Multiparameter MRI Response Assessment in a Phase I Trial of Hypofractionated Stereotactic Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas
Olya Stringfield1, John Arrington2, Solmaz Sahebjam3, and Natarajan Raghunand1
1Cancer Imaging & Metabolism, Moffitt Cancer Center, Tampa, FL, United States, 2Radiology, Moffitt Cancer Center, Tampa, FL, United States, 3Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States
In this ongoing phase 1 study, we are investigating combined pembrolizumab and bevacizumab therapy with hypofractionated
radiotherapy in recurrent glioma. The objective of this work is to develop a non-invasive
response assessment measure using multiparameter MRI (mpMRI) scans acquired as part of clinical care which may
precede volumetric changes in response to therapy.
This abstract and the presentation materials are available to members only;
a login is required.
